NCNA 6-K SEC Filing Analysis

Latest settled — T+5d

NCNA ▼ -10.14% at T+5d

NEUTRAL call ✗ call lost -10.14% · α vs SPY -7.39% · entry $2.17 → $1.95

Next anchor: T+20d in 15d

Last close $1.95 (close Jun 12) · -10.14% from $2.17 entry

Entry anchored
May 29, 01:50 PM ET
via Databento tick

T+1d

-4.61%

call -4.61% · α -4.75%

$2.07

settled 13d ago

T+5d

-10.14%

call -10.14% · α -7.39%

$1.95

settled 7d ago

T+20d

—

call — · α —

—

in 15d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

NuCana plc announced the appointment of Ian Webster as permanent Chief Financial Officer, effective June 1, 2026. Webster had served as Interim CFO since June 2025 and as Director of Finance since 2019. The filing is a routine management change with no material financial data, though the press release notes a cash runway anticipated into 2029 and upcoming Phase 2 data readouts for NUC-7738.

Actionable Insight

This CFO appointment is routine and unlikely to move the stock. Monitor upcoming Phase 2 data readouts for NUC-7738 in 2026 as the next catalyst. The cash runway into 2029 reduces near-term dilution risk but is not a new disclosure.

Key Facts

Ian Webster appointed permanent CFO, effective June 1, 2026; previously Interim CFO since June 2025 and Director of Finance since 2019.
Webster has over 20 years of finance experience, including roles at Kyowa Kirin International plc and PricewaterhouseCoopers LLP.
Company reiterates plans to generate data in 2026 from Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda for PD-1 inhibitor-resistant metastatic melanoma.
Cash runway anticipated to extend into 2029 per forward-looking statement in the press release.

Financial Impact

No financial figures reported; cash runway guidance is forward-looking and not quantified in the filing.

Risk Factors

Clinical-stage biotech with no approved products; pipeline failure risk remains high.
Forward-looking cash runway depends on no material changes in operating plan or unexpected expenses.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (8 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001193125-26-249817
Document: d247626d6k.htm	0001193125-26-249817
Document: 0001193125-26-249817-index-headers.html	0001193125-26-249817
Document: 0001193125-26-249817-index.html	0001193125-26-249817
Document: 0001193125-26-249817.txt	0001193125-26-249817

5 reports for NCNA

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for NCNA — sortable, filterable
	Type				Now
Jun 8, 2026 6d ago	6-K NEUTRAL ★ 2/10	$1.97 awaiting T+5	awaiting T+5	—	$1.95 (−1.02%)
Jun 1, 2026 13d ago	6-K NEUTRAL ★ 3/10	$2.17 $1.95	▼ −10.14%	▼ −7.39%	$1.95 (−10.14%)
May 14, 2026 4w ago	6-K BULLISH ★ 6/10	$2.18 $2.02	▼ −7.34%	▼ −8.30%	$1.95 (−10.55%)
May 6, 2026 5w ago	6-K BEARISH ★ 5/10	$2.09 $1.87	▲ +10.53%	▲ +12.03%	$1.95 (+6.70%)
Mar 19, 2026 12w ago	Press Release MIXED ★ 6/10	$1.65 $1.40	▼ −15.15%	▼ −13.00%	$1.95 (+18.18%)

US Market Status

Market Closed — Opens in 4h 37m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access